BLOG
![FDA Warning on Xylazine: Mitigating Human Risk](https://pharma.solutions/wp-content/uploads/2023/11/Blog-Featured-Images-1600x880-25-1080x675.png)
FDA Warning on Xylazine: Mitigating Human Risk
FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
Recent Articles
![New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies](https://pharma.solutions/wp-content/uploads/2023/07/Blog-Featured-Images-1600x880-16-1080x675.png)
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5,...
![Navigating the Prescription Drug Reform Act: A New Landscape for Drug Manufacturers in Florida](https://pharma.solutions/wp-content/uploads/2023/07/Blog-Featured-Images-1600x880-15-1080x675.png)
Navigating the Prescription Drug Reform Act: A New Landscape for Drug Manufacturers in Florida
Navigating the Prescription Drug Reform Act: A New Landscape for Drug Manufacturers in Florida | by: Kelly DiBattista, Esq., Research Director |...
![Short-Dated Drug Return Scheme Becomes Short-Dated](https://pharma.solutions/wp-content/uploads/2023/07/Blog-Featured-Images-1600x880-10-1080x675.png)
Short-Dated Drug Return Scheme Becomes Short-Dated
| Short-Dated Drug Return Scheme Becomes Short-Dated | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5, 2023 | Returns in the Drug...
![Alabama’s New Rule Has Massive DSCSA Implications on State Regulations](https://pharma.solutions/wp-content/uploads/2023/05/shutterstock_531425050-1080x675.jpg)
Alabama’s New Rule Has Massive DSCSA Implications on State Regulations
Alabama’s New Rule Has Massive DSCSA Implications on State Regulations | by: Sumeet Singh, Founder & Chairman | Article Posted: May 24, 2023 |...
![FDA – OA REMS Announcement Concerning requirements to Manufacturers of Opioids](https://pharma.solutions/wp-content/uploads/2023/04/Blog-Featured-Images-1600x880-12-1080x675.png)
FDA – OA REMS Announcement Concerning requirements to Manufacturers of Opioids
New FDA - OA REMS Announcement | by: Deneen Fumich, RPh | Article Posted: May 2, 2023 | April 21, 2022, FDA published in the Federal Register open...
![Oklahoma Pharmacy Board Unanimously Approves New Rules for Shipping Mail-Order Medications](https://pharma.solutions/wp-content/uploads/2023/04/Blog-Featured-Images-1600x880-8-1080x675.png)
Oklahoma Pharmacy Board Unanimously Approves New Rules for Shipping Mail-Order Medications
| New Oklahoma Rules for Shipping Mail-Order Medications | by: Deneen Fumich, RPh | Article Posted: April 5, 2023 | Pharma Solutions reported on...